Stadt- und Raumentwicklung Großbritannien

Die britische Stadt- und Raumplanung ist zentralistisch geprägt bei paralleler Bemühung um mehr lokale Steuerungsmöglichkeiten. Flexible Planungsinstrumente bedingen geringe Planungssicherheit. Das Vertrauen auf Public Private Partnership bei Planungen und bei der Finanzierung lokaler Infrastruktur ist groß

Socio-spatial relations and the governance of city-regional growth : a comparative analysis of two European high-tech regions

Oxford-Oxfordshire, UK, and the Verband Region Stuttgart or the Metro Region in Germany are two of Europe’s high-tech powerhouses, facing similar challenges concerning housing and infrastructure provision and accommodating regional as well as local economic growth. Based on desktop studies and semi-structured expert interviews, this paper examines the respective institutional, political and cultural contexts for strategic planning in the two distinct settings, aiming to identify the evolving balance of socio-spatial dimensions influencing each case. While the interplay of territory, place, scale and network is different across the two cases, both face ongoing dilemmas. In the Stuttgart region, an established and smoothly running economic and spatial growth-machine has stuttered as growth has reached capacity and localities have asserted their constitutional controls on urban expansion. In Oxford (and the wider county of Oxfordshire), there has been a contrasting dislocation between an emerging growth agenda and a fractured governance context that is historically less oriented towards growth. Additionally, Oxfordshire has operated since 2010 against the background of localism in English planning and an increasing reliance on city and housing/growth ‘deals’ negotiated with central government to access planning flexibilities and infrastructure funding. Conclusions are drawn with the aim of mutual learning from the different international experiences and of informing approaches to strategic and inter-municipal planning

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.

We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors : a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT

Allogeneic hematopoietic cell transplantation (allo-HCT) remains a treatment option for patients with chronic myeloid leukemia (CML) who fail to respond to tyrosine kinase inhibitors (TKIs). While imatinib seems to have no adverse impact on outcomes after transplant, little is known on the effects of prior use of second-generation TKI (2GTKI). We present the results of a prospective non-interventional study performed by the EBMT on 383 consecutive CML patients previously treated with dasatinib or nilotinib undergoing allo-HCT from 2009 to 2013. The median age was 45 years (18-68). Disease status at transplant was CP1 in 139 patients (38%), AP or >CP1 in 163 (45%), and BC in 59 (16%). The choice of 2GTKI was: 40% dasatinib, 17% nilotinib, and 43% a sequential treatment of dasatinib and nilotinib with or without bosutinib/ponatinib. With a median follow-up of 37 months (1-77), 8% of patients developed either primary or secondary graft failure, 34% acute and 60% chronic GvHD. There were no differences in post-transplant complications between the three different 2GTKI subgroups. Non-relapse mortality was 18% and 24% at 12 months and at 5 years, respectively. Relapse incidence was 36%, overall survival 56% and relapse-free survival 40% at 5 years. No differences in post-transplant outcomes were found between the three different 2GTKI subgroups. This prospective study demonstrates the feasibility of allo-HCT in patients previously treated with 2GTKI with a post-transplant complications rate comparable to that of TKI-naive or imatinib-treated patients.Peer reviewe

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation : a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

Non peer reviewe

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation : a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (PPeer reviewe

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation

Abstract One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA

Monitoring brownfield housing development: strengths and weaknesses of indicator based monitoring in the English planning system

In England quantified targets for the reuse of brownfields and of existing buildings place particular requirements on the planning system as part of the overall strategy to make effective use of natural resources. Achieving these targets is not free of obstacles and potential conflicts. Therefore monitoring of policy implementation is a necessity in the planning system. In addition challenging targets for increased housing provision have been introduced. In view of this the dichotomy of adequate housing-land supply without compromising environmental quality must be addressed. As a consequence monitoring will play an increasingly important role. This paper explores how these challenges can be met. It draws upon practical experience across all planning tiers to highlight the potential and limitations of indicator based monitoring.

Brownfield development: Are we using the right targets? Evidence from England and Germany

Urban brownfield sites are a major planning concern across Europe, and most European countries have strategies to reuse them. In England and Germany, quantified targets for brownfield development have been set at the national level, with the twin objectives of furthering urban regeneration and reducing greenfield development. This paper explores the implications of these quantified targets, particularly with respect to their ability to contribute to meeting these twin objectives. It explores their shortcomings and highlights implementation problems